Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults (aged 18 and over):

• People aged 18 or over with a confirmed type of blood cancer that carries a specific protein called CD19 — this includes certain types of leukaemia (ALL, CLL) or lymphoma (DLBCL, FL, or MCL)
• People with ALL (a type of leukaemia) whose cancer has come back or stopped responding to treatment, including after a bone marrow transplant from a donor (at least 6 months prior), after two or more previous treatments, or whose cancer never fully responded to at least two treatments
• People with CLL (a type of leukaemia) whose cancer came back within 2 years of chemotherapy, or who have not responded to or cannot tolerate certain targeted therapies, or whose cancer returned after a donor bone marrow transplant
• People with DLBCL (an aggressive lymphoma) whose cancer has not responded to a second or later round of chemotherapy, or has returned after a stem cell transplant
• People with FL (a slower-growing lymphoma) whose cancer returned within 2 years of chemotherapy and who are not suitable for, or have not benefited from, a stem cell transplant or a specific targeted treatment
• People with MCL (a type of lymphoma) whose cancer returned after standard first treatment and who are not suitable for, or have not benefited from, a specific targeted therapy
• People whose cancer is still measurable or detectable at the time of enrolment
• People with a life expectancy of at least 12 weeks
• People who are well enough to carry out basic daily activities (assessed using a standard medical scale)
• People whose kidneys, liver, lungs, and heart are functioning at an adequate level, based on blood tests and heart scans
• People with sufficient numbers of certain white blood cells in their blood
• Women who could become pregnant, and men, who agree to use highly effective contraception for one year after receiving the treatment
• People who are able to understand what the trial involves and who provide written consent before any trial screening takes place

Children and teenagers (aged 3 to under 18):

• Children and teenagers aged over 3 and under 18 with confirmed CD19+ ALL (a type of leukaemia)
• Young people whose ALL has come back or not responded to treatment, including after a donor bone marrow transplant (at least 6 months prior), after two or more previous treatments, or whose cancer never fully responded to at least two treatments
• Young people whose cancer is still measurable or detectable at the time of enrolment
• Young people with a life expectancy of at least 12 weeks
• Young people who are well enough to carry out basic daily activities (assessed using an age-appropriate standard medical scale)
• Young people whose kidneys, liver, lungs, and heart are functioning at an adequate level
• Young people with sufficient numbers of certain white blood cells in their blood
• Young women who could become pregnant, and post-pubertal males, who agree to use highly effective contraception for one year after receiving the treatment
• Written consent must be provided by the young person and/or their legal guardian before any trial screening takes place

Who may not be able to join:

Adults (aged 18 and over):

• People currently taking immune-suppressing medications, unless the dose is at or below a low threshold (confirm with trial site)
• People whose chemotherapy or immunotherapy has not been stopped at least 2 weeks before the cell collection procedure (though treatment may continue between cell collection and the preparation phase)
• People who have received a donor immune cell infusion (DLI) within the past 6 weeks
• People with active or ongoing graft-versus-host disease (a complication that can occur after a donor transplant)
• People with uncontrolled active hepatitis B or C
• People who are HIV-positive
• People with a serious, uncontrolled infection (bacterial, viral, or fungal)
• People with severe ongoing health conditions such as uncontrolled high blood pressure, serious heart failure, uncontrolled diabetes, or uncontrolled high cholesterol
• People who have had unstable chest pain or a heart attack within the past 3 months
• People with a current or previous separate cancer — with exceptions for: certain treated skin cancers, cervical or breast cancer in remission for at least 3 years with no recurrence, CLL or FL that has transformed into the type of lymphoma being studied, or any cancer that has been in complete remission for at least 5 years
• Women who are pregnant or breastfeeding
• People who have a known intolerance to the ingredients used in preparing the cell treatment
• People currently participating in another clinical trial at the time of screening
• People with severe CNS (brain/spinal cord) disease at a specific stage at the time of the pre-treatment assessment (confirm with trial site)

Children and teenagers (aged 3 to under 18):

• Young people currently taking immune-suppressing medications above a low weight-based dose threshold (confirm with trial site)
• Young people whose chemotherapy or immunotherapy has not been stopped at least 2 weeks before the cell collection procedure
• Young people who have received a donor immune cell infusion (DLI) within the past 6 weeks
• Young people with active or ongoing graft-versus-host disease
• Young people with uncontrolled active hepatitis B or C
• Young people who are HIV-positive
• Young people with a serious, uncontrolled infection (bacterial, viral, or fungal)
• Young people with a severe ongoing health condition (such as a life-limiting genetic disorder) — though young people with Down Syndrome are not excluded
• Young people with a current or previous separate cancer — with exceptions for lymphoma that has transformed into the type of leukaemia being studied, or any cancer that has been in complete remission for at least 5 years
• Young women who are pregnant or breastfeeding
• Young people with a known intolerance to the ingredients used in preparing the cell treatment
• Young people currently participating in another clinical trial at the time of screening
• Young people with severe CNS (brain/spinal cord) disease at a specific stage at the time of the pre-treatment assessment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.